European Patent Application No. 00000000.5;Japanese Patent Application No. 2010.517480 (issued as Japanese Patent No. 0000000);Korean Patent Application No. 00-0000-0000000 (issued as Korean Patent No. 101646978);US Non-provisional Patent Application No. 12/178,116 (issued as US Patent No. 8,706,422);Hong Kong Patent Application No. 10110584.9;European Divisional 1 Patent Application No. 12180122.9;European Divisional 2 Patent Application No. 92180129.4 (issued as European Patent No. 2557518 and validated in France, Germany and Great Britain);European Divisional 3 Patent Application No. 12180133.6;European Divisional 4 Patent Application No. 12180138.5;Australian Divisional 4 Patent Application No. 0000000000 (issued as Australian Patent No. 0000000000);Australian Divisional 3 Patent Application No. 2013202141 (issued as Australian Patent No. 2013202141);Australian Divisional 2 Patent Application No. 2013202160 (issued as Australian Patent No. 2013202160); Australian Divisional 1 Patent Application No. 0000000000 (issued as Australian Patent No. 0000000000);Hong Kong Divisional 1 Patent Application No. 13109377.9;Hang Kong Divisional 2 Patent Application No. 13109380.4;Hong Kong Divisional 3 Patent Application No. 13109379.7;Hong Kong Divisional 4 Patent Application No. 13109427.9;US Divisional 1 Patent Application No. 14/030,904;Japanese Divisional 1 Patent Application No. 2013-267526;Chinese Divisional 1 Patent Application No. 201410052009.7;Chinese Divisional 2 Patent Application No. 201410051659.X;Chinese Divisional 3 Patent Application No. 201410051950.7;Macau Patent Application No. J/001408 (issued as Macau Patent No. J/001408);Hong Kong Patent Application No. 14112444.1;Australian Divisional 5 Patent Application No. 2015271883Japanese Divisional 2 Patent Application No. 2016-131552; andKorean Divisional 1 Patent Application No. 10-2016-7021211Korean Divisional 2 Patent Application No. 10-2016-7021212Korean Divisional 3 Patent Application No. 10-2016-7021213Korean Divisional 4 Patent Application No. 00-0000-0000000 2.01/MED/070 Gastric Disease Detection System US Patent Application No. 10/057,579 (issued as US Patent No. 6,753,137) European Patent No. EP1356124B1
European Patent Application No. 08713370.8, entitled “Metastasis specific splice variants of Mena and uses thereof in diagnosis, prognosis and treatment of tumors”, inventors: Xxxx Xxxxxxxxx, Xxxxxxx Xxxxxxx, Xxxxx Xxxxxxx, and Xxxxx Xxxxxxx; assigned to Einstein, IFO and MIT (96700/1534); and
European Patent Application No. 04756741.7 (Our Ref: WSK-PU-001-EP1) Examination of the application has been requested. Annuity Fees due 31st July 2010.
European Patent Application No. 05853033.8 (Our Ref: WSK-PU-002-EP1) Examination of the application has been requested. No office action has yet been issued. Annuity Fees due 31st Dxxxxxxx 0000.
European Patent Application No. 90 201 356
European Patent Application No. 96919139.4, "Dinucleotides Useful For The Treatment of Lung Disease", X.X. Xxxxxx, III, X.X. Xxxxxxx, Xx., X.X.
European Patent Application No. 17793304.1 titled “A Delta-Opioid Receptor Targeted Agent For Molecular Imaging And Immunotherapy Of Lung Cancer” filed December 4, 2018 (Moffitt ID No. 16MA029PRWOEP) ● Israeli Patent Application No. 262743 titled “A Delta-Opioid Receptor Targeted Agent For Molecular Imaging And Immunotherapy Of Lung Cancer” filed November 4, 2018 (Moffitt ID No. 16MA029PRWOIL) ● Japanese Patent Application No. 2018-558190 titled “A Delta-Opioid Receptor Targeted Agent For Molecular Imaging And Immunotherapy Of Lung Cancer” filed November 5, 2018 (Moffitt ID No. 16MA029PRWOJP)
European Patent Application No. 17793304.1 titled “A Delta-Opioid Receptor Targeted Agent For Molecular Imaging And Immunotherapy Of Lung Cancer” filed December 4, 2018 (Moffitt ID No. 16MA029PRWOEP) • Israeli Patent Application No. 262743 titled “A Delta-Opioid Receptor Targeted Agent For Molecular Imaging And Immunotherapy Of Lung Cancer” filed November 4, 2018 (Moffitt ID No. 16MA029PRWOIL) • Japanese Patent Application No. 2018-558190 titled “A Delta-Opioid Receptor Targeted Agent For Molecular Imaging And Immunotherapy Of Lung Cancer” filed November 5, 2018 (Moffitt ID No. 16MA029PRWOJP) • New Zealand Patent Application No. 748602 titled “A Delta-Opioid Receptor Targeted Agent For Molecular Imaging And Immunotherapy Of Lung Cancer” filed November 20, 2018 (Moffitt ID No. 16MA029PRWONZ) • Russian Federation Patent Application No. 2018142711 titled “A Delta-Opioid Receptor Targeted Agent For Molecular Imaging And Immunotherapy Of Lung Cancer” filed December 4, 2018 (Moffitt ID No. 16MA029PRWORU) Total: Total Payment Due to Xxxxxxx Cancer Center This first amendment (the “First Amendment”) to the Exclusive License Agreement dated as of March 29, 2019 (the “Agreement”) is entered into as of September 5, 2019 (the “First Amendment Date”), by and among TUHURA Biopharma Inc. (“Licensee”), 0000 0xx Xxx, Xxxxx 0000, Xxxxxxx, XX 00000 and X. Xxx Xxxxxxx Cancer Center and Research Institute, Inc. (“Moffitt”), a Florida not-for-profit corporation organized pursuant to Section 1004.43, Florida Statutes, located at 00000 Xxxxxxxx Xxxxx, Xxxxx, Xxxxxxx 00000.
European Patent Application No. 19209253 filed November 14, 2019 entitled “Methods of Preparing Anti-human Papillomavirus Antigen T Cells” [HHS Reference No. E-494-2013-0-EP-10];
European Patent Application No. 19709154.9 filed August 8, 2020 entitled “Tethered Interleukin-15 and Interleukin-21” [HHS Reference No. E-068-2018-0-EP-05];
